Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended December 31, 1995
Business Overview: BD operates in Medical Supplies and Devices and Diagnostic Systems segments. The company reported strong growth driven by safety product conversions and international expansion, partially offset by the prior year's divestiture of its glove business and ongoing marketplace cost containment initiatives.
Key Financial Metrics
| Metric | Q4 1995 | Q4 1994 |
|---|---|---|
| Revenues | $639.9 million | $593.5 million |
| Net Income | $44.5 million | $33.5 million |
| Earnings Per Share (EPS) | $0.65 | $0.46 |
| Operating Income | $71.9 million | $59.6 million |
| Gross Profit Margin | 45.5% | 44.9% |
| Operating Margin | 11.2% | 10.0% |
| Cash from Operations | $88.8 million | $105.5 million |
| Total Debt (Short + Long Term) | $778.5 million | N/A (Derived from balance sheet) |
| Cash and Equivalents | $199.2 million | $119.0 million (Closing Q4 1994) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 8% year-over-year. A weaker dollar contributed an estimated $9 million (1.5 percentage points) to this growth.
- Profitability: Net income rose 33% to $44.5 million. EPS increased 41% to $0.65, driven by operating income growth and share repurchases.
- Segment Performance:
- Medical Supplies & Devices: Up 8% (7% excluding currency). International Medical grew 12% (8% excluding currency) due to safety product adoption.
- Diagnostic Systems: Up 7% (6% excluding currency). Domestic Diagnostic grew only 2% due to cost containment pressures, while International Diagnostic grew 14% (11% excluding currency).
- Expense Management: Selling and administrative expenses improved as a percentage of revenue (28.4% vs. 28.9% prior year) despite increased strategic investments. R&D spending increased 6% to $37.3 million.
- Capital Structure: Total debt increased by $15 million. The debt-to-capitalization ratio improved to 36.5% from 40.4% a year ago.
Outlook, Risks, and Management Commentary
- Share Repurchases: The company repurchased 1.2 million shares for $80 million in the quarter. Management expects to spend less than $300 million on repurchases for the full year, with authorization remaining for an additional 2.9 million shares.
- Dividends: The quarterly dividend was increased from $0.205 to $0.23 per share.
- Capital Expenditures: Q4 spending was $31 million. Full-year capital expenditures are projected at approximately $150 million.
- Acquisitions: $10 million was spent in the quarter to complete acquisitions in infectious disease and sample collection businesses.
- Risks and Contingencies:
- Cost Containment: Diagnostic segment growth is unfavorably impacted by marketplace cost containment initiatives.
- Divestiture Impact: Domestic Medical revenues were negatively affected by the absence of sales from the previously divested glove business.
- Shareholder Rights Plan: A new shareholder rights plan was adopted, issuing one Right per outstanding share upon expiration of existing rights in April 1996.
Investor Verification Checklist
- Verify the sustainability of the 8% revenue growth given the one-time impact of the weaker dollar and the reduction in promotional activity from the prior year.
- Monitor the Diagnostic segment's ability to offset cost containment pressures with innovative, cost-effective products.
- Confirm the execution of the $150 million full-year capital expenditure plan and the integration of recent acquisitions.
- Track the remaining $220 million+ capacity for share repurchases and its impact on future EPS.
- Review the terms of the new shareholder rights plan adopted in November 1995.